Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued on Saturday.
Separately, Cantor Fitzgerald reiterated a "neutral" rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.
Get Our Latest Analysis on Supernus Pharmaceuticals
Supernus Pharmaceuticals Stock Down 2.1%
Shares of Supernus Pharmaceuticals stock traded down $0.68 during mid-day trading on Friday, hitting $32.28. The stock had a trading volume of 909,294 shares, compared to its average volume of 474,594. The firm has a 50-day moving average of $32.14 and a two-hundred day moving average of $34.19. The firm has a market cap of $1.81 billion, a P/E ratio of 29.08 and a beta of 0.71. Supernus Pharmaceuticals has a 12-month low of $25.55 and a 12-month high of $40.28.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of SUPN. Raiffeisen Bank International AG acquired a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth approximately $25,000. Financial Management Professionals Inc. acquired a new position in Supernus Pharmaceuticals during the first quarter worth $30,000. Versant Capital Management Inc boosted its position in shares of Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock worth $37,000 after buying an additional 1,109 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at $41,000. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at $42,000.
Supernus Pharmaceuticals Company Profile
(
Get Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Read More
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
